Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

Introduction: Dacomitinib is an epidermal growth factor receptor (EGFR) inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in the first line in patients with EGFR activating mutations. Dacomitinib is taken orally once daily at 45 mg with or without food, until dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Garcia, Ana, Tan, Weiwei, Li, Jerry, Haughey, May, Masters, Joanna, Hibma, Jennifer, Lin, Swan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238139/
https://www.ncbi.nlm.nih.gov/pubmed/32272733
http://dx.doi.org/10.3390/pharmaceutics12040330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238139/
https://www.ncbi.nlm.nih.gov/pubmed/32272733
http://dx.doi.org/10.3390/pharmaceutics12040330

Ejemplares similares